Ensysce Amends 8-K: Upsizes Cy Biopharma Deal Financing to $77M, Fixes Conversion Ratio
ENSC has more than doubled off its 52-week low of $0.23 on elevated volume (32× avg).
Summary
Ensysce's amended 8-K corrects the Series C conversion ratio and upsizes the Cy Biopharma acquisition financing to $77 million, providing critical runway but diluting existing holders to ~7.6% ownership.
Key Events · M&A and Partnerships · ENSC
-
Acquisition of Cy Biopharma
Ensysce acquired Cy Biopharma in a stock-for-stock merger, issuing 282,122 shares of Series C Preferred Stock (convertible into 282.1M common shares) to Cy Biopharma equityholders, who will own ~75% of the combined company post-close.
-
Upsized Financing to $77M
Total financing package increased to $77M: $21.5M initial private placement (66,811 Series C shares at $321.79/share), $17.1M cash from Cy Biopharma's pre-acquisition convertible notes, and up to $38.6M milestone tranche (53,449 shares at $402.24/share).
-
Extreme Dilution for Existing Holders
Post-close, existing Ensysce shareholders will own only ~7.6% of the combined entity on a fully diluted basis (excluding milestone shares), with new investors holding ~17.5%.
-
Conversion Ratio Correction
Amendment fixes a scrivener's error: each Series C Preferred share converts into 1,000 common shares, subject to stockholder approval under Nasdaq rules.
Analysis · ENSC · Life Sciences
This amendment to the original 8-K filed earlier today corrects a scrivener's error in the Series C Preferred Stock conversion ratio (now explicitly 1,000 common shares per preferred share) and upsizes the total financing package to $77 million — $21.5 million initial close, $17.1 million in Cy Biopharma cash, and up to $38.6 million in milestone-linked tranches. The corrected press release also reveals a higher fee to Tungsten Partners ($200,000 vs. $100,000). For a micro-cap company with a going-concern warning and Nasdaq delisting risk, this acquisition and financing pivot the entire investment thesis — the combined entity gains a clinical-stage neuroplastogenic therapy with FDA Orphan Drug Designation and a cash runway into 2028, but existing shareholders face extreme dilution (Cy Biopharma equityholders will own ~75% post-close).
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.